Science & Medicine
Home | Current Issue | Archives | Subscriptions | Contact Us

Log In | Search | Author Index | Advertising

Chemokine Receptors in Anti-HIV Therapy

W. Garrett Nichols
From: Science & Medicine: Volume 10 Number 3: Page 146 (June 2005)

View Full TextAdd To BasketPurchase Images

Abstract: The past decade has witnessed remarkable strides in the control of the HIV and AIDS. Highly active antiretroviral therapy (HAART) for the first time enabled profound and sustained reductions in plasma HIV-1 RNA levels in many individuals. Unfortunately, HAART does not completely eliminate HIV-1 from the host; HIV is known for its capacity to develop resistance to antiretroviral agents; and side effects are problematic. The search for new targets for therapy has led to a new class of anti-HIV compounds, the entry inhibitors. One injectable compound (T20, enfuvirtide) has already been approved for treatment of advanced HIV infection. Several orally bioavailable agents with different targets are currently under development, including those that prevent the binding of HIV to CD4 or the chemokine co-receptors. The chemokine receptors CCR5 and CXCR4 are particularly promising targets for drug development.

Back to Table of Contents



Science & Medicine, Inc.
P.O. Box 313, Narberth, PA 19072
(610) 660-8097       (800) 888-0028
fax (610) 660-0348
e-mail editor@sciandmed.com
See our other journal: Medical Problems of Performing Artists.
Home | Current Issue | Archives | Subscriptions | Contact Us

Log In | Search | Author Index | Advertising

Copyright © 2002-2019, Science & Medicine, Inc.

Powered by Pliner Solutions, Inc.
Web Development by Pliner Solutions, Inc.